LY 297802: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9889093 |
| SCHEMBL ID | 995360 |
| MeSH ID | M0266554 |
| Synonym |
|---|
| ly-297802 |
| nnc 11-1053 |
| ly297802 |
| ly-297,802 |
| vedaclidine |
| nnc-11-1053 |
| (3-(3-1-butylthio)-1,2,5-thiadiazol-4-yl)-1-azabicyclo(2.2.2)octane |
| ly 297802 |
| 98iw5hav1n , |
| 141575-50-0 |
| (s)-3-(4-(butylthio)-1,2,5-thiadiazol-3-yl)quinuclidine |
| unii-98iw5hav1n |
| 3-(3-1-butylthio)-1,2,5-thiadiazol-4-yl)-1-azabicyclo(2.2.2)octane |
| vedaclidine [inn] |
| vedaclidine [who-dd] |
| SCHEMBL995360 |
| DTXSID30275663 |
| 3-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-4-butylsulfanyl-1,2,5-thiadiazole |
| Excerpt | Reference | Relevance |
|---|---|---|
| " These procedures provide two direct, although non-statistical, means to communicate synergism in drug combination studies." | ( Communicating synergism in drug combination studies. Brodkin, J; Shannon, HE, 2000) | 0.31 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quantification of impurities in drug substances and dosage forms using HPLC assays with UV detection is often done by comparison to a standard of the drug itself." | ( Investigation of response factor ruggedness for the determination of drug impurities using high-performance liquid chromatography with ultraviolet detection. Argentine, MD; Olsen, BA, 1997) | 0.3 |
| " The dose-response curve was shifted dose dependently to the right by the muscarinic antagonist scopolamine but not by the opioid antagonist naltrexone." | ( Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic. Bymaster, FP; Calligaro, DO; Delapp, NW; Hansen, KT; Mitch, CH; Olesen, PH; Sauerberg, P; Shannon, HE; Sheardown, MJ; Suzdak, PD; Swedberg, MD; Ward, JS, 1997) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (70.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.68) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||